EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tumor‐Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers

Kristijan Skok iD, Umberto Maccio, Spencer D Martin, Konstantin Bräutigam

Cancer Medicine · 2025

DOI: 10.1002/cam4.71023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kristijan Skok und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Breast Neoplasms, Genital Neoplasms, Female. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Javna Agencija za Raziskovalno Dejavnost RS, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The growing success of cancer immunotherapies has led to significant advances in oncology. However, despite these promising developments, cancer‐related mortality remains high for common cancer types such as breast and lower female genital tract cancers.

Method

Here, we synthesize recent findings on the prognostic relevance of tumor‐infiltrating lymphocytes (TILs) in breast, endometrial, tubo‐ovarian, and vulvar cancer. Our analysis covers the relationship between TIL counts and density, immune cell subtype combinations, immunotherapy approaches, and patient outcomes.

Results

High TIL infiltration, especially CD8 + T‐cells, generally correlates with improved outcomes such as in endometrial cancer (especially the POLE ‐ultramutated subgroup), invasive breast cancer, and ovarian epithelial tumors. However, in ductal carcinoma in situ (DCIS) of the breast, elevated TIL counts are linked to a worse prognosis. Ethnicity, the tumor microenvironment (TME), and molecular profiles further complicate the prognostic utility of TILs.

Conclusions

TIL‐based therapies have shown potential in personalized immunotherapy, particularly in recurrent, refractory ovarian cancer. Limited research on rarer gynecologic tumors hinders broader clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingBreast NeoplasmsGenital Neoplasms, FemaleHumansFemaleTumor MicroenvironmentPrognosisImmunotherapy

Stichwörter der Autor:innen

breast cancerendometrial cancerfallopian tubeimmunotherapyovarian cancerreviewtumor microenvironment (TME)tumor‐infiltrating lymphocytes (TILs)vulvar cancer

Autor:innen und Institutionen

  • Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Institute of Biomedical Sciences, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
  • Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Centre for Evolution and Cancer, Institute of Cancer Research, London, UK.

ORCID-Profile: Kristijan Skok

Förderung

  • Javna Agencija za Raziskovalno Dejavnost RS
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Skok, K., Maccio, U., Martin, S. D., & Bräutigam, K. (2025). Tumor‐Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers. Cancer Medicine. https://doi.org/10.1002/cam4.71023

Vancouver

Skok K, Maccio U, Martin SD, Bräutigam K. Tumor‐Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers. Cancer Medicine. 2025. doi:10.1002/cam4.71023

BibTeX
@article{Skok2025,
  author = {Skok, Kristijan and Maccio, Umberto and Martin, Spencer D and Bräutigam, Konstantin},
  title = {Tumor‐Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71023}
}
Kostenlos starten →